Screener / SEC EDGAR /CIK 0000851520 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Industrials · Management Consulting Services

Exponent Inc EXPO

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What EXPO's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Exponent Reports Third Quarter 2026 Financial Results

Open on SEC

EXHIBIT 99.1 Exponent Reports Third Quarter 2026 Financial Results MENLO PARK, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the third quarter of fiscal year 2026 ended October 2, 2026.

“Exponent delivered another strong quarter, with double-digit growth in revenues and earnings, reflecting continued demand for our specialized, integrated engineering and scientific expertise,” stated Dr. Catherine Corrigan, Chief Executive Officer. “User research studies continued to be a strong contributor to our growth, as clients move quickly to understand how people interact with technology across a widening range of devices and applications. Reactive work also grew, on top of a strong prior-year quarter, with increased dispute-related and failure analysis demand in the chemical, consumer products and transportation industries.

“These results reflect the durable, long-term trends shaping our business, including rapid technological innovation, increasing complexity, investment in critical infrastructure, and rising societal expectations for safety and reliability. As artificial intelligence and other digital technologies become increasingly embedded into physical systems, the digital and physical worlds are converging. Exponent is differentiated at that convergence, where data and computation meet real-world evidence, and where technology must ultimately work for the user. Our multidisciplinary scientists and engineers bring together deep domain expertise, scientific rigor, and an understanding of complex physical systems to help clients innovate with confidence, solve their most challenging problems, and manage high-consequence risk,” Dr. Corrigan continued.

Total revenues and revenues before reimbursements for the third quarter of 2026 increased 18% to $173.7 million and 12% to $153.1 million, respectively, as compared to $147.1 million and $137.1 million in the third quarter of 2025.

Net income increased to $30.9 million, or $0.64 per diluted share, in the third quarter of 2026, as compared to $28.0 million, or $0.55 per diluted share, in the same period of 2025. The tax benefit associated with share-based awards was immaterial in both the third quarter of 2026 and 2025. Inclusive of the tax benefit, Exponent’s consolidated tax rate was 28.0% in the third quarter of 2026, as compared to 27.4% for the same period in 2025.

EBITDA increased to $45.0 million, or 29.4% of revenues before reimbursements, in the third quarter of 2026, as compared to $38.8 million, or 28.3% of revenues before reimbursements in the third quarter of 2025.

Total revenues and revenues before reimbursements for the first three quarters of 2026 increased 18% to $511.6 million and 11% to $453.7 million, respectively, as compared to $434.6 million and $407.4 million in the same period of 2025.

Net income increased to $89.9 million, or $1.83 per diluted share, through the first three quarters of 2026, as compared to $81.2 million, or $1.58 per diluted share, in the same period of 2025. During the first three quarters of 2026, we realized a negative tax impact associated with share-based awards of $0.8 million, as compared to $0.4 million during the same period one year ago. Inclusive of the tax impact associated with share-based awards, Exponent’s consolidated tax rate was 28.7% through the first three quarters of 2026, as compared to 28.2% for the same period last year.

EBITDA increased to $130.8 million, or 28.8% of revenues before reimbursements, through the first three quarters of 2026, as compared to $113.4 million, or 27.8% of revenues before reimbursements, in the same period of 2025.

Through the first three quarters of 2026, Exponent paid $46.1 million in dividends, repurchased $146.1 million of common stock, and closed the period with $114.7 million in cash and cash equivalents.

In a separate press release today, Exponent announced its quarterly cash dividend of $0.31 to be paid on December 18, 2026, and reiterated its intent to continue to pay quarterly dividends.

Exponent’s engineering and other scientific segment represented 85% of the Company’s revenues before reimbursements in the third quarter and through the first three quarters of 2026. Revenues before reimbursements in this segment increased 13% in the third quarter and through the first three quarters of 2026, as compared to the prior year period. Growth during the quarter was driven by strong user research activity spanning a broad set of challenges, including health applications, dynamic and unstructured real-world environments, and sensory perception. Dispute-related services involving chemical facilities, consumer products and advanced transportation technologies also drove growth in the quarter, as clients rely on Exponent in critical, high-stakes situations.

Exponent’s environmental and health segment represented 15% of the Company’s revenues before reimbursements in the third quarter and through the first three quarters of 2026. Revenues before reimbursements in this segment increased 3% in the third quarter and 4% through the first three quarters of 2026, as compared to the prior year period. Growth in this segment was driven by increased projects assessing the effects of chemicals on human health and the environment.

“Our ability to scale our operating model in response to market demand resulted in 77% utilization and expanded profitability during the third quarter of 2026. We are encouraged by the market opportunities across the industries we serve and continue to strategically build upon our diversified portfolio of talent and capabilities,” commented Eric Anderson, Chief Financial Officer. “As we close out 2026, we are raising our full-year revenue and margin guidance, reflecting the strength of our year-to-date performance and our outlook for the remainder of the year. Looking ahead, we remain confident in Exponent’s long-term growth trajectory and our ability to capitalize on the strong demand for our differentiated expertise.”

For the fourth quarter of fiscal 2026 as compared to the same period one year prior, Exponent anticipates:

For the full fiscal year 2026 as compared to fiscal year 2025, Exponent anticipates:

“Rapid innovation continues to reshape industries as companies race to make physical products more intelligent, while expectations for safety, reliability, and performance continue to rise. Exponent is built for this moment. We help clients navigate these increasingly complex challenges, whether validating AI- enabled systems, strengthening critical infrastructure, or understanding how people interact with the technologies around them. Across these areas, our integrated platform brings the scientific and engineering expertise needed to deliver explainability, clarity, and trust. This distinctive ecosystem, together with strong long-term growth drivers, positions Exponent to deliver sustainable value for our clients and shareholders,” concluded Dr. Corrigan.

Exponent will discuss its financial results in more detail on a conference call today, Thursday, October 29, 2026, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (844) 481-2781 or (412) 317-0672. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (855) 669-9658 or (412) 317-0088 and entering passcode 5957331#.

EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation, and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income, and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present, and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

Exponent has provided its outlook regarding EBITDA as a percentage of revenues before reimbursements. The Company has not reconciled this non-GAAP financial measure to the corresponding GAAP financial measure because guidance for the various reconciling items is not provided and the Company is unable to estimate with reasonable certainty the effect of these items without unreasonable effort. For example, the Company is unable to estimate with reasonable certainty the impact of equity awards on Exponent’s taxes without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on Exponent’s results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this release is provided in the financial tables at the end of this release.

Exponent brings together 90+ technical disciplines and 950+ consultants to help our clients navigate the increasing complexity of more than a dozen industries, connecting decades of pioneering work in failure analysis to develop solutions for a safer, healthier, more sustainable world.

Exponent’s consultants deliver the highest value by leveraging multidisciplinary expertise and resources from across Exponent’s offices in North America, Asia, and Europe. Exponent’s consultants, laboratories, databases, and computing resources work seamlessly together around the globe, enabling us to produce the breakthrough insights needed to help multinational companies, startups, law firms, insurance companies, governments, and society respond to incidents and push their products and processes forward.

Exponent may be reached at (888) 656-EXPO, [email protected], or www.exponent.com.

This news release contains, and incorporates by reference, certain “forward- looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. When used in this document and in the documents incorporated herein by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward- looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in generally applicable and industry-specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

Full text with the tables
                                                                    EXHIBIT 99.1
             Exponent Reports Third Quarter 2026 Financial Results              
MENLO PARK, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq:
EXPO) today reported financial results for the third quarter of fiscal year 2026
ended October 2, 2026.

“Exponent delivered another strong quarter, with double-digit growth in revenues
and earnings, reflecting continued demand for our specialized, integrated
engineering and scientific expertise,” stated Dr. Catherine Corrigan, Chief
Executive Officer. “User research studies continued to be a strong contributor
to our growth, as clients move quickly to understand how people interact with
technology across a widening range of devices and applications. Reactive work
also grew, on top of a strong prior-year quarter, with increased dispute-related
and failure analysis demand in the chemical, consumer products and
transportation industries.

“These results reflect the durable, long-term trends shaping our business,
including rapid technological innovation, increasing complexity, investment in
critical infrastructure, and rising societal expectations for safety and
reliability. As artificial intelligence and other digital technologies become
increasingly embedded into physical systems, the digital and physical worlds are
converging. Exponent is differentiated at that convergence, where data and
computation meet real-world evidence, and where technology must ultimately work
for the user. Our multidisciplinary scientists and engineers bring together deep
domain expertise, scientific rigor, and an understanding of complex physical
systems to help clients innovate with confidence, solve their most challenging
problems, and manage high-consequence risk,” Dr. Corrigan continued.

Third Quarter Financial Results

Total revenues and revenues before reimbursements for the third quarter of 2026
increased 18% to $173.7 million and 12% to $153.1 million, respectively, as
compared to $147.1 million and $137.1 million in the third quarter of 2025.

Net income increased to $30.9 million, or $0.64 per diluted share, in the third
quarter of 2026, as compared to $28.0 million, or $0.55 per diluted share, in
the same period of 2025. The tax benefit associated with share-based awards was
immaterial in both the third quarter of 2026 and 2025. Inclusive of the tax
benefit, Exponent’s consolidated tax rate was 28.0% in the third quarter of
2026, as compared to 27.4% for the same period in 2025.

EBITDA increased to $45.0 million, or 29.4% of revenues before reimbursements,
in the third quarter of 2026, as compared to $38.8 million, or 28.3% of revenues
before reimbursements in the third quarter of 2025.

Year to Date Financial Results

Total revenues and revenues before reimbursements for the first three quarters
of 2026 increased 18% to $511.6 million and 11% to $453.7 million, respectively,
as compared to $434.6 million and $407.4 million in the same period of 2025.

Net income increased to $89.9 million, or $1.83 per diluted share, through the
first three quarters of 2026, as compared to $81.2 million, or $1.58 per diluted
share, in the same period of 2025. During the first three quarters of 2026, we
realized a negative tax impact associated with share-based awards of $0.8
million, as compared to $0.4 million during the same period one year ago.
Inclusive of the tax impact associated with share-based awards, Exponent’s
consolidated tax rate was 28.7% through the first three quarters of 2026, as
compared to 28.2% for the same period last year.

EBITDA increased to $130.8 million, or 28.8% of revenues before reimbursements,
through the first three quarters of 2026, as compared to $113.4 million, or
27.8% of revenues before reimbursements, in the same period of 2025.

Through the first three quarters of 2026, Exponent paid $46.1 million in
dividends, repurchased $146.1 million of common stock, and closed the period
with $114.7 million in cash and cash equivalents.

In a separate press release today, Exponent announced its quarterly cash
dividend of $0.31 to be paid on December 18, 2026, and reiterated its intent to
continue to pay quarterly dividends.

Business Overview

Exponent’s engineering and other scientific segment represented 85% of the
Company’s revenues before reimbursements in the third quarter and through the
first three quarters of 2026. Revenues before reimbursements in this segment
increased 13% in the third quarter and through the first three quarters of 2026,
as compared to the prior year period. Growth during the quarter was driven by
strong user research activity spanning a broad set of challenges, including
health applications, dynamic and unstructured real-world environments, and
sensory perception. Dispute-related services involving chemical facilities,
consumer products and advanced transportation technologies also drove growth in
the quarter, as clients rely on Exponent in critical, high-stakes situations.

Exponent’s environmental and health segment represented 15% of the Company’s
revenues before reimbursements in the third quarter and through the first three
quarters of 2026. Revenues before reimbursements in this segment increased 3% in
the third quarter and 4% through the first three quarters of 2026, as compared
to the prior year period. Growth in this segment was driven by increased
projects assessing the effects of chemicals on human health and the environment.

Business Outlook

“Our ability to scale our operating model in response to market demand resulted
in 77% utilization and expanded profitability during the third quarter of 2026.
We are encouraged by the market opportunities across the industries we serve and
continue to strategically build upon our diversified portfolio of talent and
capabilities,” commented Eric Anderson, Chief Financial Officer. “As we close
out 2026, we are raising our full-year revenue and margin guidance, reflecting
the strength of our year-to-date performance and our outlook for the remainder
of the year. Looking ahead, we remain confident in Exponent’s long-term growth
trajectory and our ability to capitalize on the strong demand for our
differentiated expertise.”

For the fourth quarter of fiscal 2026 as compared to the same period one year
prior, Exponent anticipates:

For the full fiscal year 2026 as compared to fiscal year 2025, Exponent
anticipates:

“Rapid innovation continues to reshape industries as companies race to make
physical products more intelligent, while expectations for safety, reliability,
and performance continue to rise. Exponent is built for this moment. We help
clients navigate these increasingly complex challenges, whether validating AI-
enabled systems, strengthening critical infrastructure, or understanding how
people interact with the technologies around them. Across these areas, our
integrated platform brings the scientific and engineering expertise needed to
deliver explainability, clarity, and trust. This distinctive ecosystem, together
with strong long-term growth drivers, positions Exponent to deliver sustainable
value for our clients and shareholders,” concluded Dr. Corrigan.

Today's Conference Call Information

Exponent will discuss its financial results in more detail on a conference call
today, Thursday, October 29, 2026, starting at 4:30 p.m. Eastern Time / 1:30
p.m. Pacific Time. The audio of the conference call is available by dialing
(844) 481-2781 or (412) 317-0672. A live webcast of the call will be available
on the Investor Relations section of the Company's website at
www.exponent.com/investors. For those unable to listen to the live webcast, a
replay of the call will also be available on the Exponent website, or by dialing
(855) 669-9658 or (412) 317-0088 and entering passcode 5957331#.

Use of non-GAAP Financial Measures

EBITDA is a non-GAAP financial measure defined by the Company as net income
before income taxes, interest income, depreciation, and amortization. EBITDAS is
a non-GAAP financial measure defined by the Company as EBITDA before stock-based
compensation. The Company regards EBITDA and EBITDAS as useful measures of
operating performance and cash flow to complement operating income, net income,
and other GAAP financial performance measures. Additionally, management believes
that EBITDA and EBITDAS provide meaningful comparisons of past, present, and
future operating results. Generally, a non-GAAP financial measure is a numerical
measure of a company's performance, financial position, or cash flow that either
excludes or includes amounts that are not normally excluded or included in the
most directly comparable measure calculated and presented in accordance with
GAAP. These measures, however, should be considered in addition to, and not as a
substitute or superior to, operating income, cash flows, or other measures of
financial performance prepared in accordance with GAAP.

Exponent has provided its outlook regarding EBITDA as a percentage of revenues
before reimbursements. The Company has not reconciled this non-GAAP financial
measure to the corresponding GAAP financial measure because guidance for the
various reconciling items is not provided and the Company is unable to estimate
with reasonable certainty the effect of these items without unreasonable effort.
For example, the Company is unable to estimate with reasonable certainty the
impact of equity awards on Exponent’s taxes without unreasonable effort. These
items are uncertain, depend on various factors, and may have a material effect
on Exponent’s results computed in accordance with GAAP. A reconciliation between
the historical GAAP and non-GAAP financial measures presented in this release is
provided in the financial tables at the end of this release.

About Exponent

Exponent brings together 90+ technical disciplines and 950+ consultants to help
our clients navigate the increasing complexity of more than a dozen industries,
connecting decades of pioneering work in failure analysis to develop solutions
for a safer, healthier, more sustainable world.

Exponent’s consultants deliver the highest value by leveraging multidisciplinary
expertise and resources from across Exponent’s offices in North America, Asia,
and Europe. Exponent’s consultants, laboratories, databases, and computing
resources work seamlessly together around the globe, enabling us to produce the
breakthrough insights needed to help multinational companies, startups, law
firms, insurance companies, governments, and society respond to incidents and
push their products and processes forward.

Exponent may be reached at (888) 656-EXPO, [email protected], or
www.exponent.com.

Forward Looking Statements

This news release contains, and incorporates by reference, certain “forward-
looking” statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995, and the rules promulgated pursuant to the
Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as
amended) that are based on the beliefs of the Company’s management, as well as
assumptions made by and information currently available to the Company’s
management. When used in this document and in the documents incorporated herein
by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect”
and similar expressions, as they relate to the Company or its management,
identify such forward-looking statements. Such statements reflect the current
views of the Company or its management with respect to future events and are
subject to certain risks, uncertainties and assumptions. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, the Company’s actual results, performance, or achievements could
differ materially from those expressed in, or implied by, any such forward-
looking statements. Factors that could cause or contribute to such material
differences include the possibility that the demand for our services may decline
as a result of changes in generally applicable and industry-specific economic
conditions, the timing of engagements for our services, the effects of
competitive services and pricing, the absence of backlog related to our
business, our ability to attract and retain key employees, the effect of tort
reform and government regulation on our business, and liabilities resulting from
claims made against us. Additional risks and uncertainties are discussed in our
Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the
report. The inclusion of such forward-looking information should not be regarded
as a representation by the Company or any other person that the future events,
plans, or expectations contemplated by the Company will be achieved. The Company
undertakes no obligation to release publicly any updates or revisions to any
such forward-looking statements.

Source: Exponent, Inc.
                                                                                
  EX…                                                                           
  IN…                                                                           
  CO…                                                                           
  CO…                                                                           
  ST…                                                                           
  OF                                                                            
  IN…                                                                           
  For                                                                           
  the                                                                           
  Qu…                                                                           
  En…                                                                           
  Oc…                                                                           
  2,                                                                            
  20…                                                                           
  and                                                                           
  Oc…                                                                           
  3,                                                                            
  20…                                                                           
 ────────────────────────────────────────────────────────────────────────────── 
  (u…                                                                           
  (in                                                                           
  th…                                                                           
  ex…                                                                           
  per                                                                           
  sh…                                                                           
  da…                                                                           
                      Quar…                          Nine                       
                      Ended                         Mont…                       
                                                    Ended                       
                      Octo…          Octo…          Octo…          Octo…        
                         2,             3,             2,             3,        
                       2026           2025           2026           2025        
  Re…                                                                           
       Reve…                                                                    
       befo…              $  153…        $  137…        $  453…        $  407…  
       reim…                                                                    
       Reim…                 20,…           10,…           57,…           27,…  
              Rev…           173…           147…           511…           434…  
  Op…                                                                           
  ex…                                                                           
       Comp…                                                                    
       and                   90,…           87,…           282…           261…  
       rela…                                                                    
       expe…                                                                    
       Other                                                                    
       oper…                 13,…           12,…           39,…           36,…  
       expe…                                                                    
       Reim…                 20,…           10,…           57,…           27,…  
       expe…                                                                    
       Gene…                                                                    
       and                   7,3…           7,6…           20,…           18,…  
       admi…                                                                    
       expe…                                                                    
                             131…           118…           400…           343…  
              Ope…           41,…           29,…           111…           90,…  
              inc…                                                              
  Ot…                                                                           
  in…                                                                           
  (e…                                                                           
  net                                                                           
       Inte…                                                                    
       inco…                  668           2,3…           3,1…           7,3…  
       net                                                                      
       Misc…                                                                    
       inco…                  448           7,2…           11,…           15,…  
       (exp…                                                                    
       net                                                                      
                             1,1…           9,5…           14,…           22,…  
              Inc…                                                              
              bef…           42,…           38,…           126…           113…  
              inc…                                                              
              tax…                                                              
  In…                        12,…           10,…           36,…           31,…  
  ta…                                                                           
              Net         $  30,…        $  28,…        $  89,…        $  81,…  
              inc…                                                              
  Net                                                                           
  in…                                                                           
  per                                                                           
  sh…                                                                           
       Basic              $  0.64        $  0.55        $  1.84        $  1.59  
       Dilu…              $  0.64        $  0.55        $  1.83        $  1.58  
  Sh…                                                                           
  us…                                                                           
  in                                                                            
  per                                                                           
  sh…                                                                           
  co…                                                                           
       Basic                 48,…           50,…           48,…           51,…  
       Dilu…                 48,…           51,…           49,…           51,…  
                                                                                
                                                                                
  EXPON…                                                                        
  INC.                                                                          
  CONDE…                                                                        
  CONSO…                                                                        
  BALAN…                                                                        
  SHEETS                                                                        
  Octob…                                                                        
  2,                                                                            
  2026                                                                          
  and                                                                           
  Janua…                                                                        
  2,                                                                            
  2026                                                                          
 ────────────────────────────────────────────────────────────────────────────── 
  (unau…                                                                        
  (in                                                                           
  thous…                                                                        
                                      Octob…                Janua…              
                                      2,                    2,                  
                                                 2026                  2026     
                           Assets                                               
  Curre…                                                                        
  asset…                                                                        
          Cash                                                                  
          and                         $       114,689       $       221,930     
          cash                                                                  
          equiva…                                                               
          Accoun…                                                               
          receiv…                             209,604               181,507     
          net                                                                   
          Prepaid                                                               
          expens…                                                               
          and                                  28,976                24,143     
          other                                                                 
          assets                                                                
                   Total                                                        
                   curre…                     353,269               427,580     
                   assets                                                       
  Prope…                                                                        
  equip…                                                                        
  and                                          69,900                71,981     
  lease…                                                                        
  impro…                                                                        
  net                                                                           
  Opera…                                                                        
  lease                                        68,208                73,376     
  right…                                                                        
  asset                                                                         
  Goodw…                                        8,607                 8,607     
  Other                                       193,092               195,975     
  assets                                                                        
                                      $       693,076       $       777,519     
                           Liabil…                                              
                           and                                                  
                           Stockh…                                              
                           Equity                                               
  Curre…                                                                        
  liabi…                                                                        
          Accoun…                                                               
          payable                                                               
          and                         $        34,733       $        30,942     
          accrued                                                               
          liabil…                                                               
          Accrued                                                               
          payroll                                                               
          and                                 121,993               121,302     
          employ…                                                               
          benefi…                                                               
          Deferr…                              18,503                18,868     
          revenu…                                                               
          Operat…                                                               
          lease                                 6,533                 6,890     
          liabil…                                                               
                   Total                                                        
                   curre…                     181,762               178,002     
                   liabi…                                                       
  Other                                       128,822               133,232     
  liabi…                                                                        
  Opera…                                                                        
  lease                                        74,606                75,944     
  liabi…                                                                        
                   Total                      385,190               387,178     
                   liabi…                                                       
  Stock…                                                                        
  equit…                                                                        
          Common                                   66                    66     
          stock                                                                 
          Additi…                                                               
          paid-in                             392,784               369,747     
          capital                                                               
          Accumu…                                                               
          other                                (2,496  )             (2,290  )  
          compre…                                                               
          loss                                                                  
          Retain…                             712,318               668,423     
          earnin…                                                               
          Treasu…                                                               
          stock,                              (794,7…  )            (645,6…  )  
          at cost                                                               
                           Total                                                
                           stockh…            307,886               390,341     
                           equity                                               
                                      $       693,076       $       777,519     
                                                                                
                                                                                
  E…                                                                            
  I…                                                                            
  E…                                                                            
  a…                                                                            
  E…                                                                            
  (…                                                                            
  F…                                                                            
  t…                                                                            
  Q…                                                                            
  E…                                                                            
  O…                                                                            
  2,                                                                            
  2…                                                                            
  a…                                                                            
  O…                                                                            
  3,                                                                            
  2…                                                                            
 ────────────────────────────────────────────────────────────────────────────── 
  (…                                                                            
  (…                                                                            
  t…                                                                            
                  Qua…                            Nine                          
                  End…                            Mon…                          
                                                  End…                          
                  Oct…            Oct…            Oct…            Oct…          
                  2,              3,              2,              3,            
                        20…             20…             20…             20…     
  N…              $     30…       $     28…       $     89…       $     81…     
  I…                                                                            
  A…                                                                            
  b…                                                                            
  (…                                                                            
      In…               12…             10…             36…             31…     
      ta…                                                                       
      In…                                                                       
      in…               (6…  )          (2…  )          (3…  )          (7…  )  
      net                                                                       
      De…                                                                       
      and               2,…             2,…             7,…             7,…     
      am…                                                                       
           EB…          44…             38…             13…             11…     
           (1)                                                                  
      St…               6,…             5,…             22…             18…     
      co…                                                                       
           EB…    $     51…       $     44…       $     15…       $     13…     
           (1)                                                                  
  (…                                                                            
  E…                                                                            
  is                                                                            
  a                                                                             
  n…                                                                            
  f…                                                                            
  m…                                                                            
  d…                                                                            
  by                                                                            
  t…                                                                            
  C…                                                                            
  as                                                                            
  n…                                                                            
  i…                                                                            
  b…                                                                            
  i…                                                                            
  t…                                                                            
  i…                                                                            
  i…                                                                            
  d…                                                                            
  a…                                                                            
  a…                                                                            
  E…                                                                            
  is                                                                            
  a                                                                             
  n…                                                                            
  f…                                                                            
  m…                                                                            
  d…                                                                            
  by                                                                            
  t…                                                                            
  C…                                                                            
  as                                                                            
  E…                                                                            
  b…                                                                            
  s…                                                                            
  c…                                                                            
  T…                                                                            
  C…                                                                            
  r…                                                                            
  E…                                                                            
  a…                                                                            
  E…                                                                            
  as                                                                            
  u…                                                                            
  m…                                                                            
  of                                                                            
  o…                                                                            
  p…                                                                            
  a…                                                                            
  c…                                                                            
  f…                                                                            
  to                                                                            
  c…                                                                            
  o…                                                                            
  i…                                                                            
  n…                                                                            
  i…                                                                            
  a…                                                                            
  o…                                                                            
  G…                                                                            
  f…                                                                            
  p…                                                                            
  m…                                                                            
  A…                                                                            
  m…                                                                            
  b…                                                                            
  t…                                                                            
  E…                                                                            
  a…                                                                            
  E…                                                                            
  p…                                                                            
  m…                                                                            
  c…                                                                            
  of                                                                            
  p…                                                                            
  p…                                                                            
  a…                                                                            
  f…                                                                            
  o…                                                                            
  r…                                                                            
  G…                                                                            
  a                                                                             
  n…                                                                            
  f…                                                                            
  m…                                                                            
  is                                                                            
  a                                                                             
  n…                                                                            
  m…                                                                            
  of                                                                            
  a                                                                             
  c…                                                                            
  p…                                                                            
  f…                                                                            
  p…                                                                            
  or                                                                            
  c…                                                                            
  f…                                                                            
  t…                                                                            
  e…                                                                            
  e…                                                                            
  or                                                                            
  i…                                                                            
  a…                                                                            
  t…                                                                            
  a…                                                                            
  n…                                                                            
  n…                                                                            
  e…                                                                            
  or                                                                            
  i…                                                                            
  in                                                                            
  t…                                                                            
  m…                                                                            
  d…                                                                            
  c…                                                                            
  m…                                                                            
  c…                                                                            
  a…                                                                            
  p…                                                                            
  in                                                                            
  a…                                                                            
  w…                                                                            
  G…                                                                            
  T…                                                                            
  m…                                                                            
  h…                                                                            
  s…                                                                            
  be                                                                            
  c…                                                                            
  in                                                                            
  a…                                                                            
  t…                                                                            
  a…                                                                            
  n…                                                                            
  as                                                                            
  a                                                                             
  s…                                                                            
  or                                                                            
  s…                                                                            
  t…                                                                            
  o…                                                                            
  i…                                                                            
  c…                                                                            
  f…                                                                            
  or                                                                            
  o…                                                                            
  m…                                                                            
  of                                                                            
  f…                                                                            
  p…                                                                            
  p…                                                                            
  in                                                                            
  a…                                                                            
  w…                                                                            
  G…                                                                            
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXPO/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.